As the specialty care global business unit of Sanofi, we are focused on rare diseases, rare blood disorders, multiple sclerosis, oncology and immunology. More than 30 years since we began, we remain just as committed to and passionate about advancing therapies that offer hope to patients and families.

Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world’s leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing.

Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology. In 2018, with the acquisitions of Bioverativ and Ablynx, we further expanded our focus to include rare blood disorders, bringing deep expertise in hematology.

Our ambition is to be the industry leader in specialty care. We currently provide more than 25 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.
Driven by our commitment to patients, we strive to develop strong relationships with our patient communities, listening to their perspectives so that we can truly understand their needs. These collaborations continue to guide and motivate us as we work to push the boundaries of medicine and technology to develop new and better therapies where none existed before.